Eli Lilly has expanded its partnership with Gate Bioscience in a new multi-year agreement that could exceed $870 million, extending a relationship the companies began in July 2025 around a new small-molecule drug class.
Both collaborations use Gate’s Molecular Gate discovery engine to eliminate specific difficult-to-drug extracellular proteins in diseases with high unmet need. Gate calls the resulting candidates “molecular gates.” The new deal adds one target to the companies’ existing work and includes an opportunity to add a second target, according to Gate.
The financial structure keeps the emphasis on option value rather than immediate scale. Gate will receive an undisclosed upfront payment and another payment if a second target is selected. The biotech is also eligible for preclinical, clinical and commercial milestone payments, plus tiered royalties on global net sales of any approved products. In return, Lilly receives an exclusive worldwide license to research, develop and commercialize products from the collaboration.
Why the expansion matters
The immediate signal is that Lilly is choosing to add to an early platform relationship rather than wait for public validation. The first deal, signed in July 2025, was worth up to $856 million. This second pact, at more than $870 million in potential value, suggests Lilly sees enough progress in the ongoing work to widen the bet.
Gate will continue to lead discovery, while Lilly will handle work from later-stage preclinical development through commercialization. That division is typical of platform alliances, but it is also revealing: Lilly appears to be buying access to a discovery capability while keeping control of the expensive downstream path.
Neither company disclosed the number of targets they had previously been pursuing together, and they did not name disease indications in the new announcement. Gate said, however, that the approximately 4,000 targets addressable by molecular gates include many high-value proteins in immunology, neuroscience and cardiometabolic health, as well as targets for which no therapies are approved or for which current treatment requires injectables.
The capital picture
For Gate, the repeat collaboration adds strategic validation on top of recent private financing. The company was founded in 2021 and raised $65 million in an oversubscribed Series B round in November 2025, bringing total funding to $135 million at that time. Lilly joined that round as a new investor, alongside lead investor Forbion. Gate had previously launched with a $60 million Series A in 2023.
As part of the original alliance, Gate was also eligible to receive preclinical R&D support from Lilly ExploR&D, part of Lilly Catalyze360. Taken together, the expanded deal and prior equity participation show Lilly using more than one mechanism to stay close to a platform that is still at the discovery stage. In a funding environment that often demands later validation, that is a notable sign of where capital is still willing to flow: platforms that promise access to hard biological targets with a modality large companies do not yet fully own.
